Portal de Periódicos da CAPES

Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia

1992; Elsevier BV; Volume: 340; Issue: 8833 Linguagem: Inglês

10.1016/0140-6736(92)92625-p

1474-547X

Francesco Lo‐Coco, Daniela Diverio, Giuseppe Avvisati, William Arcese, M. C. Petti, G. Meloni, Franco Mandelli, P P Pandolfi, F Grignani, Pier Giuseppe Pelicci, Andrea Biondi, Valeria Rossi, Giuseppe Masera, Tiziano Barbui, Alessandro Rambaldi,

Estrogen and related hormone effects

Acute promyelocytic leukaemia (APL) is characterised by a unique fusion transcript, PML/ RARα. We tested for this transcript in 35 APL patients who were in apparent remission after various treatments. 11 of 13 patients who tested positive 4 months after achieving remission were in relapse 1-4 months later. All 22 patients who tested negative at 4 months were disease-free after a further 3 months to five years. The test may therefore prove useful in determining the need for additional treatment during clinical remission.